Natco-Alvogen Claim First Filer ANDA Status For Imbruvica Tablet Form
Executive Summary
Natco and Alvogen Pine Brook have entered the arena for a potential generic version of AbbVie/Johnson & Johnson’s Imbruvica through a US ANDA filing for the tablet version of the BTK-inhibitor.